5-aza-7-deazapurine Derivatives for Treating Flaviviridae

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes the development and use of new 5-aza-7-deazapurine derivatives, which are novel nucleoside analogues, for the treatment of infections caused by viruses from the Flaviviridae family, including hepatitis C virus, flaviviruses (such as dengue, Zika, West Nile, yellow fever), and pestiviruses. These compounds work as antiviral agents by interfering with viral replication mechanisms. The compounds can be administered alone or in combination with other antiviral agents and are suitable for both human and veterinary medicine.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of hepatitis C virus (HCV) infection in humans.
• Therapeutic intervention in flavivirus infections, such as dengue, Zika, West Nile, and yellow fever.
• Control and treatment of pestivirus infections in livestock, such as bovine viral diarrhea virus and classical swine fever virus.
• Use as part of combination antiviral therapy to reduce drug resistance and improve outcomes against RNA viruses.
• Potential use in veterinary medicine for economically important animal viruses.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides a new class of antivirals targeting Flaviviridae, offering options beyond existing therapies.
• Potentially effective against multiple viruses within the Flaviviridae family, making it a broad-spectrum antiviral.
• Can be formulated or modified (e.g., as salts or prodrugs) to improve stability, bioavailability, and delivery.
• May be used alone or in combination with other existing antiviral agents to increase treatment efficacy and reduce resistance development.
• Suitable for both human and animal (veterinary) applications, addressing significant public health and agricultural needs.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

This invention is directed to a method for treating a host, especially a human, infected with hepatitis C, flavivirus and/or pestivirus, comprising administering to that host an effective amount of an anti-flavivirus or anti-pestivirus, biologically active compound has a 5-aza-7-deazapurine moiety. The 5-aza-7-deazapurine moiety may be substituted or unsubstituted, and may comprise a non-nucleoside or nucleoside analogue, or a salt or prodrug thereof. The compound of the present invention may be administered alone or in combination with another anti-hepatitis C, anti-flavivirus and/or anti-pestivirus agent.